HYKU Biosciences
Burlington, US · Founded 2021 · Delaware corporation · 9 employees on LinkedIn · 4 known investors
Find your way into HYKU Biosciences
102 people in our graph share verified history with the HYKU Biosciences team — schools, employers, funds. One of them is your warm intro.
Clint Myersunlockedknows KLEEM CHAUDHARY · together at The University of North Carolina at Chapel Hill (overlapped)
×2knows the team · via Portal Instruments
×7knows the team · via The University of North Carolina at Chapel Hill
knows the team · via Checkmate Pharmaceuticals
knows the team · via HYKU Biosciences
Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins. The company operates in drug discovery, using its proprietary Hyku platform to address challenges such as selectivity, druggability, and resistance in disease targets.
Founders & leadership
HYKU Biosciences was founded in 2021 by KLEEM CHAUDHARY and Ku-Lung (Ken) Hsu, PhD.
KC
KLEEM CHAUDHARYinCo-founder · President & Chief Executive OfficerExecutive and director at Hyku Biosciences, which develops small molecule therapeutics designed to target disease-driving proteins through covalent binding to non-cysteine amino acids. Chaudhary has held leadership roles across multiple biotech and pharmaceutical organizations.
K(
Ku-Lung (Ken) Hsu, PhDEndowed Associate Professor of Chemistry
KC
Kleem Chaudhary, PhDPresident & CEO
Board
JG
JOHN GUSTOFSONBoard director
LB
LT
MV
JN
Investors · 4
Reported raises · per SEC filings
Form D private placements$15.2M disclosed across 2 rounds · 2025–2026
▶$8.6MraisedAug 2026 · 4 investors · OtherRule 506(b)
▶$8.6MraisedAug 2026 · 4 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- KLEEM CHAUDHARYExecutive Officer, Director
- MATTHIAS VAN WOENSELDirector
- JOHN GUSTOFSONDirector
- JANWILLEM NAESENSDirector
- Offering amount
- $8.6M
- Amount sold
- $8.6M
- First sale
- Jul 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$6.6MraisedJan 2026 · 8 investors · OtherRule 506(b)
▶$6.6MraisedJan 2026 · 8 investors · Other
Rule 506(b)Officers, directors & promoters on the filing
- JOHN GUSTOFSONDirector
- LAURA BRASSDirector
- LAURA TADVALKARDirector
- KLEEM CHAUDHARYExecutive Officer, Director, Promoter
- MATTHIAS VAN WOENSELDirector
- Offering amount
- $21M
- Amount sold
- $6.6M
- First sale
- Dec 2025
- Incorporated
- Corporation, Delaware, 2021
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 5
by search overlap
IQVIA7 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.
Bioworld5 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Harvard Bioscience5 shared keywordsHarvard Bioscience manufactures and supplies life science research tools and laboratory equipment for academic institutions and pharmaceutical companies. The company serves the research and development market with advanced instrumentation and solutions.
Helicore5 shared keywordsHelicore Bio develops long-acting antibody-peptide conjugate therapies for obesity and cardiometabolic disease, using proprietary GLP-1R agonist and amylin receptor agonist peptide libraries combined with a GIP ligand-binding antibody backbone. Its pipeline targets quarterly-dosed treatments, with a first-in-class GIP-binding antibody validated in a Phase 1 study.
Harmony Biosciences5 shared keywordsHarmony Biosciences develops innovative therapeutic treatments focused on rare neurological diseases. The company serves patients, families, and advocates in the rare disease community through novel drug development and patient-centered approaches.
Companies competing with HYKU Biosciences for the same Google search keywords, organic and paid, via search-intersection analysis.
Frequently asked questions
- What does HYKU Biosciences do?
- Hyku Biosciences develops small molecule therapeutics with novel mechanisms of action designed to covalently bind non-cysteine amino acids and inactivate disease-driving proteins. The company operates in drug discovery, using its proprietary Hyku platform to address challenges such as selectivity, druggability, and resistance in disease targets.
- Who founded HYKU Biosciences?
- HYKU Biosciences was founded by KLEEM CHAUDHARY, Ku-Lung (Ken) Hsu, PhD in 2021.
- Who are HYKU Biosciences's investors?
- HYKU Biosciences's investors include Droia Ventures, Eisai Innovation, Inc., Novartis Venture Fund, RA Capital.
- How much funding has HYKU Biosciences raised?
- HYKU Biosciences has disclosed $15.2M raised across 2 rounds.
- Where is HYKU Biosciences headquartered?
- HYKU Biosciences is headquartered in Burlington, US.